25 XP   0   0   10

NGM Biopharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse NGM Biopharmaceuticals Inc together

PenkeI guess you are interested in NGM Biopharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NGM Biopharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NGM Biopharmaceuticals Inc

I send you an email if I find something interesting about NGM Biopharmaceuticals Inc.

Quick analysis of NGM Biopharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of NGM Biopharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.78
Expected worth in 1 year
$0.45
How sure are you?
23.1%

+ What do you gain per year?

Total Gains per Share
$-1.33
Return On Investment
-86.3%

For what price can you sell your share?

Current Price per Share
$1.54
Expected price per share
$1.52 - $2.2
How sure are you?
50%

1. Valuation of NGM Biopharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.54

Intrinsic Value Per Share

$-12.24 - $-14.13

Total Value Per Share

$-10.46 - $-12.34

2. Growth of NGM Biopharmaceuticals Inc (5 min.)




Is NGM Biopharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$148.6m$287.1m-$104.2m-57.0%

How much money is NGM Biopharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$34.9m-$39.7m$4.8m13.8%
Net Profit Margin-6,603.4%-370.8%--

How much money comes from the company's main activities?

3. Financial Health of NGM Biopharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#305 / 1010

Most Revenue
#494 / 1010

Most Profit
#827 / 1010

Most Efficient
#920 / 1010

What can you expect buying and holding a share of NGM Biopharmaceuticals Inc? (5 min.)

Welcome investor! NGM Biopharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of NGM Biopharmaceuticals Inc.

What can you expect buying and holding a share of NGM Biopharmaceuticals Inc?

First you should know what it really means to hold a share of NGM Biopharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of NGM Biopharmaceuticals Inc is $1.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of NGM Biopharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in NGM Biopharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.78. Based on the TTM, the Book Value Change Per Share is $-0.33 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of NGM Biopharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.33-21.5%-0.43-27.7%-0.49-31.6%-0.34-22.2%-0.27-17.4%
Usd Book Value Change Per Share-0.25-16.5%-0.33-21.6%-0.23-14.8%-0.02-1.5%0.074.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.25-16.5%-0.33-21.6%-0.23-14.8%-0.02-1.5%0.074.4%
Usd Price Per Share0.86-2.15-11.54-13.38-10.29-
Price to Earnings Ratio-0.65--1.16--6.05--12.23--9.41-
Price-to-Total Gains Ratio-3.39--5.93--75.07--19.04--19.04-
Price to Book Ratio0.48-0.92-3.30-3.54-2.72-
Price-to-Total Gains Ratio-3.39--5.93--75.07--19.04--19.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.54
Number of shares649
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.33-0.02
Usd Total Gains Per Share-0.33-0.02
Gains per Quarter (649 shares)-215.63-14.87
Gains per Year (649 shares)-862.52-59.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-863-8730-59-69
20-1725-17360-119-128
30-2588-25990-178-187
40-3450-34620-238-246
50-4313-43250-297-305
60-5175-51880-357-364
70-6038-60510-416-423
80-6900-69140-476-482
90-7763-77770-535-541
100-8625-86400-595-600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.023.02.03.8%1.023.02.03.8%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.019.01.023.1%6.019.01.023.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.019.01.023.1%6.019.01.023.1%

Fundamentals of NGM Biopharmaceuticals Inc

About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 15:51:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NGM Biopharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit NGM Biopharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -16,769.7% means that $-167.70 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NGM Biopharmaceuticals Inc:

  • The MRQ is -16,769.7%. The company is making a huge loss. -2
  • The TTM is -6,603.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-16,769.7%TTM-6,603.4%-10,166.3%
TTM-6,603.4%YOY-370.8%-6,232.6%
TTM-6,603.4%5Y-1,458.5%-5,144.9%
5Y-1,458.5%10Y-1,123.5%-335.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16,769.7%-207.2%-16,562.5%
TTM-6,603.4%-216.8%-6,386.6%
YOY-370.8%-282.3%-88.5%
5Y-1,458.5%-436.8%-1,021.7%
10Y-1,123.5%-597.3%-526.2%
1.1.2. Return on Assets

Shows how efficient NGM Biopharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • -16.4% Return on Assets means that NGM Biopharmaceuticals Inc generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NGM Biopharmaceuticals Inc:

  • The MRQ is -16.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.4%TTM-16.5%+0.2%
TTM-16.5%YOY-11.9%-4.6%
TTM-16.5%5Y-9.3%-7.3%
5Y-9.3%10Y-7.1%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.4%-13.3%-3.1%
TTM-16.5%-12.8%-3.7%
YOY-11.9%-11.6%-0.3%
5Y-9.3%-13.8%+4.5%
10Y-7.1%-15.6%+8.5%
1.1.3. Return on Equity

Shows how efficient NGM Biopharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • -18.6% Return on Equity means NGM Biopharmaceuticals Inc generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NGM Biopharmaceuticals Inc:

  • The MRQ is -18.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.6%TTM-19.0%+0.4%
TTM-19.0%YOY-13.9%-5.1%
TTM-19.0%5Y-10.5%-8.5%
5Y-10.5%10Y-7.8%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.6%-16.9%-1.7%
TTM-19.0%-16.1%-2.9%
YOY-13.9%-14.9%+1.0%
5Y-10.5%-19.3%+8.8%
10Y-7.8%-20.1%+12.3%

1.2. Operating Efficiency of NGM Biopharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient NGM Biopharmaceuticals Inc is operating .

  • Measures how much profit NGM Biopharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -17,977.6% means the company generated $-179.78  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NGM Biopharmaceuticals Inc:

  • The MRQ is -17,977.6%. The company is operating very inefficient. -2
  • The TTM is -7,105.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-17,977.6%TTM-7,105.4%-10,872.2%
TTM-7,105.4%YOY-386.9%-6,718.5%
TTM-7,105.4%5Y-1,564.8%-5,540.6%
5Y-1,564.8%10Y-1,205.9%-358.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17,977.6%-298.0%-17,679.6%
TTM-7,105.4%-238.5%-6,866.9%
YOY-386.9%-288.4%-98.5%
5Y-1,564.8%-486.2%-1,078.6%
10Y-1,205.9%-628.4%-577.5%
1.2.2. Operating Ratio

Measures how efficient NGM Biopharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 180.78 means that the operating costs are $180.78 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NGM Biopharmaceuticals Inc:

  • The MRQ is 180.776. The company is inefficient in keeping operating costs low. -1
  • The TTM is 72.522. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ180.776TTM72.522+108.254
TTM72.522YOY4.953+67.569
TTM72.5225Y16.934+55.588
5Y16.93410Y13.429+3.505
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ180.7763.235+177.541
TTM72.5223.310+69.212
YOY4.9533.838+1.115
5Y16.9345.679+11.255
10Y13.4297.823+5.606

1.3. Liquidity of NGM Biopharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if NGM Biopharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.79 means the company has $7.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NGM Biopharmaceuticals Inc:

  • The MRQ is 7.791. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.326. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.791TTM7.326+0.465
TTM7.326YOY6.901+0.424
TTM7.3265Y7.915-0.589
5Y7.91510Y7.048+0.867
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7913.863+3.928
TTM7.3264.169+3.157
YOY6.9015.337+1.564
5Y7.9156.122+1.793
10Y7.0486.434+0.614
1.3.2. Quick Ratio

Measures if NGM Biopharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 11.73 means the company can pay off $11.73 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NGM Biopharmaceuticals Inc:

  • The MRQ is 11.733. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.626. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.733TTM11.626+0.108
TTM11.626YOY11.334+0.291
TTM11.6265Y11.509+0.116
5Y11.50910Y10.338+1.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7333.504+8.229
TTM11.6263.991+7.635
YOY11.3345.371+5.963
5Y11.5096.088+5.421
10Y10.3386.395+3.943

1.4. Solvency of NGM Biopharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of NGM Biopharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare NGM Biopharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that NGM Biopharmaceuticals Inc assets are financed with 12.0% credit (debt) and the remaining percentage (100% - 12.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NGM Biopharmaceuticals Inc:

  • The MRQ is 0.120. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.128. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.120TTM0.128-0.008
TTM0.128YOY0.143-0.016
TTM0.1285Y0.204-0.076
5Y0.20410Y0.315-0.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1200.339-0.219
TTM0.1280.337-0.209
YOY0.1430.271-0.128
5Y0.2040.368-0.164
10Y0.3150.388-0.073
1.4.2. Debt to Equity Ratio

Measures if NGM Biopharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.6% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NGM Biopharmaceuticals Inc:

  • The MRQ is 0.136. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.147. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.136TTM0.147-0.011
TTM0.147YOY0.168-0.021
TTM0.1475Y0.148-0.001
5Y0.14810Y0.147+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1360.392-0.256
TTM0.1470.403-0.256
YOY0.1680.335-0.167
5Y0.1480.427-0.279
10Y0.1470.461-0.314

2. Market Valuation of NGM Biopharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings NGM Biopharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare NGM Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.65 means the investor is paying $-0.65 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NGM Biopharmaceuticals Inc:

  • The EOD is -1.161. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.648. Based on the earnings, the company is expensive. -2
  • The TTM is -1.156. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.161MRQ-0.648-0.514
MRQ-0.648TTM-1.156+0.508
TTM-1.156YOY-6.051+4.896
TTM-1.1565Y-12.230+11.075
5Y-12.23010Y-9.408-2.822
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.161-2.300+1.139
MRQ-0.648-2.656+2.008
TTM-1.156-2.718+1.562
YOY-6.051-4.145-1.906
5Y-12.230-6.258-5.972
10Y-9.408-6.315-3.093
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NGM Biopharmaceuticals Inc:

  • The EOD is -1.388. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.774. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.232. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.388MRQ-0.774-0.614
MRQ-0.774TTM-1.232+0.458
TTM-1.232YOY-6.767+5.535
TTM-1.2325Y-16.166+14.933
5Y-16.16610Y-12.435-3.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.388-2.974+1.586
MRQ-0.774-3.306+2.532
TTM-1.232-3.508+2.276
YOY-6.767-5.613-1.154
5Y-16.166-8.378-7.788
10Y-12.435-8.873-3.562
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of NGM Biopharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.48 means the investor is paying $0.48 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NGM Biopharmaceuticals Inc:

  • The EOD is 0.865. Based on the equity, the company is cheap. +2
  • The MRQ is 0.482. Based on the equity, the company is cheap. +2
  • The TTM is 0.919. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.865MRQ0.482+0.382
MRQ0.482TTM0.919-0.436
TTM0.919YOY3.297-2.378
TTM0.9195Y3.542-2.623
5Y3.54210Y2.724+0.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8651.914-1.049
MRQ0.4822.116-1.634
TTM0.9192.097-1.178
YOY3.2972.881+0.416
5Y3.5423.550-0.008
10Y2.7243.936-1.212
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NGM Biopharmaceuticals Inc.

3.1. Institutions holding NGM Biopharmaceuticals Inc

Institutions are holding 54.164% of the shares of NGM Biopharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Column Group LLC21.730410.29171813673500
2023-12-31BlackRock Inc3.80790.00013178165-661714-17.2327
2023-12-31Vanguard Group Inc3.31950.0001277057494720.3431
2023-12-31EcoR1 Capital, LLC2.85860.05322385873-4049645-62.9265
2023-12-31StepStone Group LLC1.88510.2433157335700
2023-12-31Acadian Asset Management LLC1.60470.0045133933114536012.1745
2023-12-31Millennium Management LLC1.51250.000512623951051272497.9429
2023-12-31Euclidean Capital LLC1.18880.0959992168-992168-50
2023-12-31Geode Capital Management, LLC1.10420.0001921610347093.9135
2023-12-31State Street Corporation0.98540822399278763.5085
2023-12-31Renaissance Technologies Corp0.90690.00175689223456544.9077
2023-12-31Nuveen Asset Management, LLC0.74830.00026245327420.119
2023-12-31Two Sigma Advisers, LLC0.70320.001258690011290023.8186
2023-09-30Jacobs Levy Equity Management, Inc.0.66930.0035558604-20282-3.5036
2023-12-31Two Sigma Investments LLC0.58770.0014905168368820.5709
2023-12-31Federated Hermes Inc0.41380.0007345381-240208-41.0199
2023-12-31Northern Trust Corp0.40410.0001337282-6789-1.9731
2023-12-31GSA Capital Partners LLP0.40070.024133447312079756.5328
2023-09-30D. E. Shaw & Co LP0.38640.0004322472-32418-9.1347
2023-09-30Oak Hill Investment Management, L.P.0.36360.0152303492-44758-12.8523
Total 45.581110.736838043151-4226601-11.1%

3.2. Funds holding NGM Biopharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.52090.0001126940300
2024-03-28iShares Russell 2000 ETF1.33110.002711109945370.0484
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.71760.0009598937387006.9078
2024-01-31Fidelity Small Cap Index0.51590.0027430600297797.4295
2024-03-28iShares Russell 2000 Value ETF0.50120.0053418306-265-0.0633
2023-12-31Federated Hermes MDT Small Cap Growth IS0.40440.0623337511-41115-10.859
2023-12-31Federated Hermes MDT SCG Institutional0.40440.062337511-41115-10.859
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.36390.015530370000
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.36220.017430230100
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.31360.00126173968002.6673
2024-01-31CREF Stock R10.26250.000321905900
2023-12-31Vanguard VIF Small Co Gr0.23780.011319849800
2024-03-28Loncar Cancer Immunotherapy ETF0.23681.0931976053424820.9651
2023-12-31Bridgeway Ultra-Small Company Market0.23360.0902195000-80000-29.0909
2024-03-29Schwab US Small-Cap ETF™0.22170.001718503400
2024-02-29Vanguard Russell 2000 ETF0.18990.0025158459124608.5343
2024-02-29Vanguard Health Care ETF0.18390.00111534787840.5134
2024-02-29Fidelity Extended Market Index0.16670.0006139158-111990-44.5912
2024-03-31BlackRock Extended Equity Market K0.16340.00151363815804174.0886
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.1270.001710596900
Total 8.45851.37387059643-93136-1.3%

3.3. Insider Transactions

Insiders are holding 21.084% of the shares of NGM Biopharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-01-30Group L P ColumnBUY75425
2023-01-23Group L P ColumnBUY99005
2023-01-19Group L P ColumnBUY376395
2023-01-17Jin-long ChenSELL850825.15
2023-01-12Group L P ColumnBUY53784.95
2023-01-10Group L P ColumnBUY1000704.84
2022-12-12Group L P ColumnBUY3004.98
2022-11-21Group L P ColumnBUY359975
2022-11-03Group L P ColumnBUY1040904.99
2022-10-27David V GoeddelBUY768774.86
2022-10-25Group L P ColumnBUY510464.75
2022-10-17David V GoeddelBUY500003.18
2022-06-09Group L P ColumnBUY98416113.5
2022-06-02Group L P ColumnBUY3420013.03
2022-05-31Group L P ColumnBUY6180613.47
2022-05-26Group L P ColumnBUY2020113.49
2022-05-24Group L P ColumnBUY1782813.37
2022-05-19Group L P ColumnBUY2066613.25
2022-05-17Group L P ColumnBUY8904913.42
2022-05-11Group L P ColumnBUY8317511.25

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NGM Biopharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.254-0.332+31%-0.228-10%-0.023-91%0.068-470%
Book Value Per Share--1.7812.191-19%3.441-48%3.245-45%2.717-34%
Current Ratio--7.7917.326+6%6.901+13%7.915-2%7.048+11%
Debt To Asset Ratio--0.1200.128-6%0.143-16%0.204-41%0.315-62%
Debt To Equity Ratio--0.1360.147-7%0.168-19%0.148-8%0.147-7%
Dividend Per Share----0%-0%-0%-0%
Eps---0.332-0.426+29%-0.487+47%-0.342+3%-0.268-19%
Free Cash Flow Per Share---0.277-0.400+44%-0.438+58%-0.290+5%-0.250-10%
Free Cash Flow To Equity Per Share---0.276-0.394+43%-0.2760%-0.038-86%-0.048-83%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.923+8%
Intrinsic Value_10Y_max---14.125--------
Intrinsic Value_10Y_min---12.240--------
Intrinsic Value_1Y_max---1.418--------
Intrinsic Value_1Y_min---1.393--------
Intrinsic Value_3Y_max---4.259--------
Intrinsic Value_3Y_min---4.066--------
Intrinsic Value_5Y_max---7.098--------
Intrinsic Value_5Y_min---6.588--------
Market Cap128532096.000+44%71694201.600179423294.400-60%963364752.000-93%1116493217.280-94%858840936.369-92%
Net Profit Margin---167.697-66.034-61%-3.708-98%-14.585-91%-11.235-93%
Operating Margin---179.776-71.054-60%-3.869-98%-15.648-91%-12.059-93%
Operating Ratio--180.77672.522+149%4.953+3550%16.934+968%13.429+1246%
Pb Ratio0.865+44%0.4820.919-47%3.297-85%3.542-86%2.724-82%
Pe Ratio-1.161-79%-0.648-1.156+78%-6.051+834%-12.230+1788%-9.408+1352%
Price Per Share1.540+44%0.8592.150-60%11.543-93%13.377-94%10.290-92%
Price To Free Cash Flow Ratio-1.388-79%-0.774-1.232+59%-6.767+774%-16.166+1988%-12.435+1506%
Price To Total Gains Ratio-6.072-79%-3.387-5.927+75%-75.075+2117%-19.043+462%-19.043+462%
Quick Ratio--11.73311.626+1%11.334+4%11.509+2%10.338+13%
Return On Assets---0.164-0.165+1%-0.119-27%-0.093-44%-0.071-56%
Return On Equity---0.186-0.190+2%-0.139-25%-0.105-44%-0.078-58%
Total Gains Per Share---0.254-0.332+31%-0.228-10%-0.023-91%0.068-470%
Usd Book Value--148638000.000182874500.000-19%287166750.000-48%270812100.000-45%226804884.615-34%
Usd Book Value Change Per Share---0.254-0.332+31%-0.228-10%-0.023-91%0.068-470%
Usd Book Value Per Share--1.7812.191-19%3.441-48%3.245-45%2.717-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.332-0.426+29%-0.487+47%-0.342+3%-0.268-19%
Usd Free Cash Flow---23151000.000-33363500.000+44%-36574250.000+58%-24235100.000+5%-20064538.462-13%
Usd Free Cash Flow Per Share---0.277-0.400+44%-0.438+58%-0.290+5%-0.250-10%
Usd Free Cash Flow To Equity Per Share---0.276-0.394+43%-0.2760%-0.038-86%-0.048-83%
Usd Market Cap128532096.000+44%71694201.600179423294.400-60%963364752.000-93%1116493217.280-94%858840936.369-92%
Usd Price Per Share1.540+44%0.8592.150-60%11.543-93%13.377-94%10.290-92%
Usd Profit---27670000.000-34957000.000+26%-39771250.000+44%-28226500.000+2%-21731653.846-21%
Usd Revenue--165000.0001104250.000-85%13833250.000-99%16427200.000-99%21616192.308-99%
Usd Total Gains Per Share---0.254-0.332+31%-0.228-10%-0.023-91%0.068-470%
 EOD+5 -3MRQTTM+21 -12YOY+13 -205Y+12 -2110Y+8 -26

4.2. Fundamental Score

Let's check the fundamental score of NGM Biopharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.161
Price to Book Ratio (EOD)Between0-10.865
Net Profit Margin (MRQ)Greater than0-167.697
Operating Margin (MRQ)Greater than0-179.776
Quick Ratio (MRQ)Greater than111.733
Current Ratio (MRQ)Greater than17.791
Debt to Asset Ratio (MRQ)Less than10.120
Debt to Equity Ratio (MRQ)Less than10.136
Return on Equity (MRQ)Greater than0.15-0.186
Return on Assets (MRQ)Greater than0.05-0.164
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of NGM Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.542
Ma 20Greater thanMa 501.555
Ma 50Greater thanMa 1001.550
Ma 100Greater thanMa 2001.253
OpenGreater thanClose1.540
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -302205-97-52-14971-789618
Gross Profit  17,067-15,9391,128-824304-22282-435-353
Income Tax Expense  -1,860-687-2,54799-2,448199-2,2499,4937,244



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets168,868
Total Liabilities20,230
Total Stockholder Equity148,638
 As reported
Total Liabilities 20,230
Total Stockholder Equity+ 148,638
Total Assets = 168,868

Assets

Total Assets168,868
Total Current Assets156,444
Long-term Assets12,424
Total Current Assets
Cash And Cash Equivalents 58,815
Short-term Investments 88,369
Net Receivables 58
Other Current Assets 9,202
Total Current Assets  (as reported)156,444
Total Current Assets  (calculated)156,444
+/-0
Long-term Assets
Property Plant Equipment 7,033
Long-term Assets Other 2,936
Long-term Assets  (as reported)12,424
Long-term Assets  (calculated)9,969
+/- 2,455

Liabilities & Shareholders' Equity

Total Current Liabilities20,081
Long-term Liabilities149
Total Stockholder Equity148,638
Total Current Liabilities
Accounts payable 2,982
Other Current Liabilities 17,099
Total Current Liabilities  (as reported)20,081
Total Current Liabilities  (calculated)20,081
+/-0
Long-term Liabilities
Long-term Liabilities Other 149
Long-term Liabilities  (as reported)149
Long-term Liabilities  (calculated)149
+/-0
Total Stockholder Equity
Common Stock83
Retained Earnings -724,008
Accumulated Other Comprehensive Income 18
Other Stockholders Equity 872,545
Total Stockholder Equity (as reported)148,638
Total Stockholder Equity (calculated)148,638
+/-0
Other
Capital Stock83
Cash and Short Term Investments 147,184
Common Stock Shares Outstanding 82,803
Liabilities and Stockholders Equity 168,868
Net Debt -58,815
Net Invested Capital 148,638
Net Working Capital 136,363
Property Plant and Equipment Gross 51,874



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
> Total Assets 
276,994
248,941
237,563
237,563
246,085
246,085
231,627
396,703
390,615
380,403
360,701
347,284
326,082
329,043
445,541
423,011
415,858
402,387
359,773
337,371
335,866
307,402
258,837
220,544
192,150
168,868
168,868192,150220,544258,837307,402335,866337,371359,773402,387415,858423,011445,541329,043326,082347,284360,701380,403390,615396,703231,627246,085246,085237,563237,563248,941276,994
   > Total Current Assets 
0
175,533
191,476
191,476
214,557
214,557
199,145
368,344
364,320
355,248
338,307
322,622
302,240
308,426
425,849
403,129
395,883
379,280
337,622
318,839
315,700
288,859
242,529
204,402
177,038
156,444
156,444177,038204,402242,529288,859315,700318,839337,622379,280395,883403,129425,849308,426302,240322,622338,307355,248364,320368,344199,145214,557214,557191,476191,476175,5330
       Cash And Cash Equivalents 
45,463
25,593
38,912
38,912
56,923
56,923
47,313
265,072
303,016
245,598
256,952
249,317
253,976
147,017
148,113
99,403
145,826
151,795
109,872
63,379
101,449
73,456
67,549
53,271
51,476
58,815
58,81551,47653,27167,54973,456101,44963,379109,872151,795145,82699,403148,113147,017253,976249,317256,952245,598303,016265,07247,31356,92356,92338,91238,91225,59345,463
       Short-term Investments 
184,729
148,092
150,315
150,315
149,710
149,710
146,126
97,116
53,557
98,913
71,517
62,778
33,973
148,139
264,543
291,147
237,603
214,458
219,960
234,429
198,701
198,036
163,455
140,273
114,569
88,369
88,369114,569140,273163,455198,036198,701234,429219,960214,458237,603291,147264,543148,13933,97362,77871,51798,91353,55797,116146,126149,710149,710150,315150,315148,092184,729
       Net Receivables 
0
0
0
0
3,669
3,669
0
881
0
5,206
742
3,079
7,215
6,433
4,925
3,586
4,400
4,945
103
6,674
4,380
7,580
1,257
736
0
58
5807361,2577,5804,3806,6741034,9454,4003,5864,9256,4337,2153,0797425,206088103,6693,6690000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,945
0
0
0
0
1,499
1,499
0
0
001,4991,4990000-4,94500000000000000000
   > Long-term Assets 
0
73,408
0
46,087
0
31,528
32,482
28,359
26,295
25,155
22,394
24,662
23,842
20,617
19,692
19,882
19,975
23,107
22,151
18,532
20,166
18,543
16,308
16,142
15,112
12,424
12,42415,11216,14216,30818,54320,16618,53222,15123,10719,97519,88219,69220,61723,84224,66222,39425,15526,29528,35932,48231,528046,087073,4080
       Property Plant Equipment 
27,194
24,873
26,731
26,731
23,893
23,893
23,319
22,172
20,485
19,475
18,274
17,321
15,773
14,526
13,733
12,790
11,452
14,116
13,006
11,567
10,916
10,592
9,552
8,827
7,819
7,033
7,0337,8198,8279,55210,59210,91611,56713,00614,11611,45212,79013,73314,52615,77317,32118,27419,47520,48522,17223,31923,89323,89326,73126,73124,87327,194
       Long Term Investments 
0
0
15,944
15,944
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000015,94415,94400
       Long-term Assets Other 
0
3,385
0
3,412
0
7,635
9,163
6,187
5,810
5,680
4,120
7,341
8,069
6,091
5,959
7,092
8,523
8,991
9,145
5,466
5,296
3,997
4,301
4,860
4,838
2,936
2,9364,8384,8604,3013,9975,2965,4669,1458,9918,5237,0925,9596,0918,0697,3414,1205,6805,8106,1879,1637,63503,41203,3850
> Total Liabilities 
97,182
369,919
66,017
361,012
59,208
59,208
350,805
50,573
51,429
49,684
41,729
46,120
49,379
49,000
45,964
49,936
61,819
66,740
48,636
45,290
49,977
47,842
37,903
28,423
22,345
20,230
20,23022,34528,42337,90347,84249,97745,29048,63666,74061,81949,93645,96449,00049,37946,12041,72949,68451,42950,573350,80559,20859,208361,01266,017369,91997,182
   > Total Current Liabilities 
37,693
36,893
38,900
38,900
41,486
41,486
42,879
38,653
40,478
39,718
28,462
33,702
37,716
42,583
40,309
45,043
57,728
61,355
44,563
42,539
48,596
47,842
37,903
28,423
22,345
20,081
20,08122,34528,42337,90347,84248,59642,53944,56361,35557,72845,04340,30942,58337,71633,70228,46239,71840,47838,65342,87941,48641,48638,90038,90036,89337,693
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,077
5,153
5,229
5,307
5,385
4,073
2,751
1,381
0
01,3812,7514,0735,3855,3075,2295,1535,07700000000000000000
       Accounts payable 
8,424
1,892
4,196
4,196
5,775
5,775
4,203
3,164
4,457
9,026
3,648
1,934
1,613
9,663
7,535
5,141
7,632
5,246
4,815
6,873
3,565
8,453
13,293
5,855
4,690
2,982
2,9824,6905,85513,2938,4533,5656,8734,8155,2467,6325,1417,5359,6631,6131,9343,6489,0264,4573,1644,2035,7755,7754,1964,1961,8928,424
       Other Current Liabilities 
29,269
13,643
23,429
13,885
21,708
16,686
16,635
18,048
21,397
25,820
24,814
29,694
31,517
32,920
32,774
34,939
37,808
33,258
29,478
23,940
32,757
33,638
20,161
19,128
16,167
17,099
17,09916,16719,12820,16133,63832,75723,94029,47833,25837,80834,93932,77432,92031,51729,69424,81425,82021,39718,04816,63516,68621,70813,88523,42913,64329,269
   > Long-term Liabilities 
0
333,026
0
322,112
0
17,722
307,926
11,920
10,951
9,966
13,267
12,418
11,663
6,417
5,655
4,893
4,091
5,385
4,073
2,751
1,381
14,204
17,366
0
0
149
1490017,36614,2041,3812,7514,0735,3854,0914,8935,6556,41711,66312,41813,2679,96610,95111,920307,92617,7220322,1120333,0260
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,385
4,073
2,751
1,381
0
0
0
0
0
000001,3812,7514,0735,38500000000000000000
       Warrants
0
0
0
0
0
0
295,072
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000295,072000000
       Long-term Liabilities Other 
0
0
0
0
0
0
1,322
1,077
833
574
4,188
4,188
4,484
0
0
0
0
0
4,073
2,751
1,381
0
0
0
0
149
14900001,3812,7514,073000004,4844,1884,1885748331,0771,322000000
       Deferred Long Term Liability 
0
0
0
0
2,292
2,292
3,669
10,843
10,118
9,392
8,667
7,941
7,179
6,417
5,655
4,893
4,091
0
0
0
0
0
0
0
0
0
0000000004,0914,8935,6556,4177,1797,9418,6679,39210,11810,8433,6692,2922,2920000
> Total Stockholder Equity
179,812
-120,978
-120,978
-123,449
-108,195
186,877
-119,178
346,130
339,186
330,719
318,972
301,164
276,703
280,043
399,577
373,075
354,039
335,647
311,137
292,081
285,889
259,560
220,934
192,121
169,805
148,638
148,638169,805192,121220,934259,560285,889292,081311,137335,647354,039373,075399,577280,043276,703301,164318,972330,719339,186346,130-119,178186,877-108,195-123,449-120,978-120,978179,812
   Common Stock
11
12
13
13
7
54
7
66
66
67
68
69
69
71
77
77
78
78
78
79
82
82
82
83
83
83
83838382828279787878777771696968676666754713131211
   Retained Earnings Total Equity00-667,541-629,2800-545,196-497,935-451,416-418,966-391,732-362,867-326,175-298,631-270,640-240,875-215,259-196,144-180,203-169,286-161,617000000
   Accumulated Other Comprehensive Income 
0
-431
0
-498
0
-267
-45
102
99
25
-55
137
15
4
-18
5
-11
-129
-677
-1,077
-915
-302
-97
-149
-78
18
18-78-149-97-302-915-1,077-677-129-115-18415137-552599102-45-2670-4980-4310
   Capital Surplus 
0
0
0
0
0
39,258
42,477
515,248
519,224
526,771
534,218
541,833
547,259
578,599
725,693
735,860
745,704
754,664
763,152
791,014
831,918
0
850,229
859,728
0
0
00859,728850,2290831,918791,014763,152754,664745,704735,860725,693578,599547,259541,833534,218526,771519,224515,24842,47739,25800000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
40,890
-498
30,379
-267
356,216
-252,595
118,545
128,609
146,368
565,649
575,107
582,032
578,599
725,693
735,860
745,704
335,776
763,152
791,014
831,918
841,413
850,229
859,728
866,138
872,545
872,545866,138859,728850,229841,413831,918791,014763,152335,776745,704735,860725,693578,599582,032575,107565,649146,368128,609118,545-252,595356,216-26730,379-49840,8900



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,417
Cost of Revenue-2,221
Gross Profit2,1962,196
 
Operating Income (+$)
Gross Profit2,196
Operating Expense-148,743
Operating Income-146,547-146,547
 
Operating Expense (+$)
Research Development112,008
Selling General Administrative37,840
Selling And Marketing Expenses1,105
Operating Expense148,743150,953
 
Net Interest Income (+$)
Interest Income9,322
Interest Expense-0
Other Finance Cost-0
Net Interest Income9,322
 
Pretax Income (+$)
Operating Income-146,547
Net Interest Income9,322
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-142,375-150,719
EBIT - interestExpense = -146,547
-142,375
-142,375
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-146,547-142,375
Earnings Before Interest and Taxes (EBITDA)-144,326
 
After tax Income (+$)
Income Before Tax-142,375
Tax Provision-0
Net Income From Continuing Ops-142,375-142,375
Net Income-142,375
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses150,964
Total Other Income/Expenses Net4,172-9,322
 

Technical Analysis of NGM Biopharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of NGM Biopharmaceuticals Inc. The general trend of NGM Biopharmaceuticals Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine NGM Biopharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NGM Biopharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.63 < 2 < 2.2.

The bearish price targets are: 1.53 > 1.52 > 1.52.

Tweet this
NGM Biopharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NGM Biopharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NGM Biopharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NGM Biopharmaceuticals Inc. The current macd is 0.00528466.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NGM Biopharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for NGM Biopharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the NGM Biopharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NGM Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNGM Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NGM Biopharmaceuticals Inc. The current adx is 42.27.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy NGM Biopharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
NGM Biopharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NGM Biopharmaceuticals Inc. The current sar is 1.93035602.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NGM Biopharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NGM Biopharmaceuticals Inc. The current rsi is 48.54. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
NGM Biopharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNGM Biopharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NGM Biopharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NGM Biopharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
NGM Biopharmaceuticals Inc Daily Stochastic Oscillator ChartNGM Biopharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NGM Biopharmaceuticals Inc. The current cci is -102.16511708.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
NGM Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNGM Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NGM Biopharmaceuticals Inc. The current cmo is -12.67641632.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NGM Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNGM Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NGM Biopharmaceuticals Inc. The current willr is -90.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
NGM Biopharmaceuticals Inc Daily Williams %R ChartNGM Biopharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NGM Biopharmaceuticals Inc.

NGM Biopharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NGM Biopharmaceuticals Inc. The current atr is 0.04869016.

NGM Biopharmaceuticals Inc Daily Average True Range (ATR) ChartNGM Biopharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NGM Biopharmaceuticals Inc. The current obv is 14,233,508.

NGM Biopharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNGM Biopharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NGM Biopharmaceuticals Inc. The current mfi is 41.51.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
NGM Biopharmaceuticals Inc Daily Money Flow Index (MFI) ChartNGM Biopharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NGM Biopharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-11-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-31MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

NGM Biopharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NGM Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.542
Ma 20Greater thanMa 501.555
Ma 50Greater thanMa 1001.550
Ma 100Greater thanMa 2001.253
OpenGreater thanClose1.540
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of NGM Biopharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on NGM Biopharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about NGM Biopharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NGM Biopharmaceuticals Inc

I send you an email if I find something interesting about NGM Biopharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NGM Biopharmaceuticals Inc.

Receive notifications about NGM Biopharmaceuticals Inc in your mailbox!